论文部分内容阅读
目的探讨乳腺癌组织中上皮钙黏素(E-cadherin,Ecad)的表达与EGFR和HER-2表达的关系及临床意义。方法采用免疫组化SP法检测202例乳腺癌标本中E-cad、EGFR和HER-2的表达,分析三者表达与不同临床病理特征的关系,对有随访资料的数据运用COX比例风险模型分析多因素与患者预后的关系。结果乳腺癌中E-cad、EGFR和HER-2的阳性率分别是65.3%、43.1%、27.2%。乳腺癌中E-cad、EGFR和HER-2的表达均与TNM分期及淋巴结转移有关(P<0.05)。E-cad、EGFR和HER-2的表达与患者年龄、肿瘤大小、组织学分级无关(P>0.05),乳腺癌中E-cad的表达与EGFR和HER-2的表达均呈负相关(P<0.05)。E-cad的表达与患者生存率呈正相关(P<0.05),HER-2、临床分期与患者生存率呈负相关(P<0.05)。结论 E-cad可以抑制乳腺癌的浸润转移,其与EGFR和HER-2表达具有相关性,可能在乳腺癌的发生、发展过程中共同发挥作用,Ecad、HER-2和临床分期是影响患者预后的独立因素。
Objective To investigate the relationship between the expression of E-cadherin (E-cadherin, Ecad) and the expression of EGFR and HER-2 in breast cancer and its clinical significance. Methods The expression of E-cad, EGFR and HER-2 was detected by immunohistochemical SP method in 202 cases of breast cancer. The relationship between the three expressions and clinicopathological features was analyzed. The data of follow-up data were analyzed by COX proportional hazards model Relationship between multifactor and patient prognosis. Results The positive rates of E-cad, EGFR and HER-2 in breast cancer were 65.3%, 43.1% and 27.2%, respectively. The expression of E-cad, EGFR and HER-2 in breast cancer were correlated with TNM staging and lymph node metastasis (P <0.05). The expression of E-cad, EGFR and HER-2 had no correlation with the age, tumor size and histological grade (P> 0.05). The expression of E-cad in breast cancer was negatively correlated with the expression of EGFR and HER-2 <0.05). There was a positive correlation between the expression of E-cad and the survival rate of patients (P <0.05). The clinical stage of HER-2 was negatively correlated with the survival rate of patients (P <0.05). Conclusion E-cad inhibits the invasion and metastasis of breast cancer, which is correlated with the expression of EGFR and HER-2, which may play a role in the occurrence and development of breast cancer. The expression of Ecad, HER-2 and clinical stage affect the prognosis The independent factor.